Healthcare provider profile · identity verified

Marites Mcmurtrey, MD

Family Practice · ANAHEIM, CA · NPI 1013088087

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	433	193
Lisinopril	Lisinopril	222	83
Amlodipine Besylate	Amlodipine Besylate	205	96
Levothyroxine Sodium	Levothyroxine Sodium	202	79
Simvastatin	Simvastatin	192	69
Atenolol	Atenolol	169	70
Alendronate Sodium	Alendronate Sodium	140	52
Hydrochlorothiazide	Hydrochlorothiazide	133	53
Metformin Hcl	Metformin Hcl	133	53
Losartan Potassium	Losartan Potassium	129	64
Omeprazole	Omeprazole	128	77
Rosuvastatin Calcium	Rosuvastatin Calcium	120	55
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	119	50
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	116	48
Potassium Chloride	Potassium Chloride	113	44
Glipizide	Glipizide	93	38
Metoprolol Tartrate	Metoprolol Tartrate	83	38
Pantoprazole Sodium	Pantoprazole Sodium	69	27
Albuterol Sulfate Hfa	Albuterol Sulfate	68	45
Furosemide	Furosemide	67	33
Metformin Hcl Er	Metformin Hcl	58	29
Alprazolam	Alprazolam	53	18
Tamsulosin Hcl	Tamsulosin Hcl	49	21
Meloxicam	Meloxicam	47	36
Allopurinol	Allopurinol	43	19
Pradaxa	Dabigatran Etexilate Mesylate	43	16
Gabapentin	Gabapentin	41	21
Terazosin Hcl	Terazosin Hcl	41	19
Ibuprofen	Ibuprofen	40	26
Clopidogrel	Clopidogrel Bisulfate	38	17
Famotidine	Famotidine	35	17
Quetiapine Fumarate	Quetiapine Fumarate	34	suppressed
Ezetimibe	Ezetimibe	31	13
Triamcinolone Acetonide	Triamcinolone Acetonide	31	24
Azelastine Hcl	Azelastine Hcl	28	11
Fenofibrate	Fenofibrate	28	11
Humulin N	Insulin Nph Human Isophane	28	13
Mirtazapine	Mirtazapine	28	suppressed
Alvesco	Ciclesonide	27	suppressed
Tramadol Hcl	Tramadol Hcl	27	17
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	26	26
Cephalexin	Cephalexin	26	13
Fluoxetine Hcl	Fluoxetine Hcl	25	13
Trazodone Hcl	Trazodone Hcl	25	17
Bisoprolol Fumarate	Bisoprolol Fumarate	24	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	15
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	21	12
Fluticasone Propionate	Fluticasone Propionate	21	14
Metronidazole	Metronidazole	21	11
Memantine Hcl	Memantine Hcl	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Cefadroxil	Cefadroxil	18	18
Clonazepam	Clonazepam	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Lovastatin	Lovastatin	17	suppressed
Finasteride	Finasteride	16	suppressed
Prednisone	Prednisone	16	12
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	15	15
Naproxen	Naproxen	15	suppressed
Nystatin	Nystatin	15	suppressed
Lorazepam	Lorazepam	14	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	13	13
Hydrocortisone	Hydrocortisone	13	suppressed
Trospium Chloride	Trospium Chloride	13	suppressed
Eliquis	Apixaban	12	suppressed
Estradiol	Estradiol	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	11	suppressed
Digoxin	Digoxin	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error